Clinical trial Recruiting at 1 site Observational Ages 18 to 45 Women only

Analyzing salivary microRNA in endometriosis patients and their response to progestin therapy

Official title: Salivary MicroRNA in Endometriosis: Correlation With Progestin Treatment Response: A Prospective Observational Study

Run by University of Udine · NCT06414720 · Data updated 2026-11-12

This study is testing if analyzing saliva can help identify which women with endometriosis will respond well to a specific hormone treatment.

More Endometriosis trials

Quick facts

Study typeObservational
Ages18 Years to 45 Years
SexWomen only
Enrollment90 (estimated)
SponsorUniversity of Udine
Academic / other
Locations1 site (Udine, UD)
StatusRecruiting
StartedApril 22, 2024
Main results expectedDecember 1, 2025
Study endsDecember 1, 2025
Registry record updatedApril 2, 2025
Trial IDNCT06414720 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are women over 18 years of age with a clinical or histological diagnosis of endometriosis who are not currently undergoing progestin therapy.

Probably not a fit

Patients who are pregnant, pre-menopausal, post-menopausal, or have conditions affecting salivary miRNA measurement may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the salivary microRNA profiles of patients diagnosed with endometriosis to determine differences between those who respond to progestin therapy and those who do not. Ninety patients attending the Chronic Pelvic Pain Clinic will provide saliva samples before starting treatment with 2 mg dienogest. After four months of therapy, the researchers will evaluate the treatment response and analyze the salivary miRNA signatures to identify potential biomarkers for therapy response. The goal is to enhance non-invasive diagnostic tools for early identification and treatment of endometriosis.

Why it matters

Potential benefit: If successful, this study could lead to the development of a non-invasive biomarker for predicting treatment response in endometriosis patients.

How similar studies have gone: While there has been progress in identifying biomarkers for endometriosis, this specific approach using salivary miRNA profiles is novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
INCLUSION CRITERIA

* Age \> 18 years
* Fertile age
* Clinical-ultrasound diagnosis or histological diagnosis of endometriosis
* Informed consent

EXCLUSION CRITERIA

* Pregnancy
* Pre-menarcheal or post-menopausal status
* Chronic pelvic pain syndrome with or without central sensitization assessed with the Central Sensitization Inventory Test (CSI)
* Neoplasia, diabetes, BMI \> 30 kg/m2, coagulopathies, autoimmune diseases, or other conditions that may affect salivary miRNA measurement
* Currently undergoing progestin therapy

Where it's running

  • University of Udine
    Udine, Ud, Italy
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.